AAIC 2025 Abstract
TML‐6, A Novel Oral Multi‐Target Drug: Design of a Global Phase II Trial Investigating Safety, Tolerability, and Efficacy with Integration of Blood Biomarkers in Early Alzheimer’s Disease.
Abstract
Background: TML‐6 is a novel synthetic drug with driving mechanism of amelioration of autophagy function in neurons and microglias to remove intraneuronal and extracellular amyloid accumulation as the potential AD drug.
